Literature DB >> 22041919

Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.

Dai Mohri1, Yoshinari Asaoka, Hideaki Ijichi, Koji Miyabayashi, Yotaro Kudo, Motoko Seto, Miki Ohta, Motohisa Tada, Yasuo Tanaka, Tsuneo Ikenoue, Keisuke Tateishi, Hiroyuki Isayama, Fumihiko Kanai, Noriyoshi Fukushima, Minoru Tada, Takao Kawabe, Masao Omata, Kazuhiko Koike.   

Abstract

BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) is recognized as a precursor lesion to pancreatic cancer, a unique pathological entity. IPMN has subtypes with different clinical characteristics. However, the molecular mechanisms of cancer progression from IPMN remain largely unknown. In this study we examined the differences in genetic alteration(s) among the IPMN subtypes.
METHODS: Surgically resected IPMNs (n = 25) were classified into four subtypes by hematoxylin and eosin (H&E) and mucin immunostaining. Mutations in KRAS, BRAF, and PIK3CA genes and expression of CDKN2A, TP53, SMAD4, phospho-ERK, and phospho-SMAD1/5/8 proteins were examined.
RESULTS: There were 11 gastric, 11 intestinal, one pancreatobiliary, and two oncocytic types in this study. We then compared the two major subtypes, gastric-type and intestinal-type IPMN. Gastric-type IPMN showed a significantly higher incidence of KRAS mutations (9/11, 81.8%) compared with intestinal type (3/11, 27.3%; p < 0.05), although the intestinal type showed a higher grade of dysplasia than gastric type (p < 0.01). All cases with KRAS mutations showed phospho-ERK immunostaining. In contrast, intestinal type (9/11, 81.8%) showed more frequent SMAD1/5/8 phosphorylation compared with gastric-type IPMN (3/11, 27.3%; p < 0.05%).
CONCLUSIONS: There may be distinct mechanisms of pancreatic cancer progression in the different subtypes of IPMN. In particular, KRAS mutation and bone morphogenetic protein-SMAD signaling status may be crucial diverging steps for the two representative pathways to pancreatic cancer in IPMN patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22041919     DOI: 10.1007/s00535-011-0482-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  40 in total

1.  Missense mutations of the BRAF gene in human lung adenocarcinoma.

Authors:  Katsuhiko Naoki; Tzu-Hsiu Chen; William G Richards; David J Sugarbaker; Matthew Meyerson
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  Absence of tyrosine kinase mutations in Japanese colorectal cancer patients.

Authors:  R-X Shao; N Kato; L-J Lin; R Muroyama; M Moriyama; T Ikenoue; H Watabe; M Otsuka; B Guleng; M Ohta; Y Tanaka; S Kondo; N Dharel; J-H Chang; H Yoshida; T Kawabe; M Omata
Journal:  Oncogene       Date:  2006-10-02       Impact factor: 9.867

Review 3.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

4.  Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas.

Authors:  Barbara Chadwick; Carlynn Willmore-Payne; Sheryl Tripp; Lester J Layfield; Sharon Hirschowitz; Joseph Holden
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

5.  Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines.

Authors:  R Barros; B Pereira; I Duluc; M Azevedo; N Mendes; V Camilo; R J Jacobs; P Paulo; F Santos-Silva; I van Seuningen; G R van den Brink; L David; J-N Freund; R Almeida
Journal:  J Pathol       Date:  2008-08       Impact factor: 7.996

Review 6.  Pancreatic carcinoma.

Authors:  S Rosewicz; B Wiedenmann
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

7.  Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study.

Authors:  Toru Furukawa; Günter Klöppel; N Volkan Adsay; Jorge Albores-Saavedra; Noriyoshi Fukushima; Akira Horii; Ralph H Hruban; Yo Kato; David S Klimstra; Daniel S Longnecker; Jutta Lüttges; G Johan A Offerhaus; Michio Shimizu; Makoto Sunamura; Arief Suriawinata; Kyoichi Takaori; Suguru Yonezawa
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

8.  BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Karl C Bruckman; Nancy T Ciau; Xiaojun Li; Margaret H Lauerman; Harold Frucht; John A Chabot; John D Allendorf; Helen E Remotti; Gloria H Su
Journal:  Cancer Lett       Date:  2006-11-09       Impact factor: 8.679

Review 9.  An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Authors:  Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

10.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

View more
  27 in total

Review 1.  Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments.

Authors:  Irene Esposito; Björn Konukiewitz; Anna Melissa Schlitter; Günter Klöppel
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

2.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

3.  Pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm: a report of 8 cases.

Authors:  Koichiro Mandai; Koji Uno; Kenjiro Yasuda
Journal:  Clin J Gastroenterol       Date:  2013-05-12

Review 4.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

5.  Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.

Authors:  Janel L Kopp; Claire L Dubois; David F Schaeffer; Atefeh Samani; Farnaz Taghizadeh; Robert W Cowan; Andrew D Rhim; Bangyan L Stiles; Mark Valasek; Maike Sander
Journal:  Gastroenterology       Date:  2017-12-19       Impact factor: 22.682

6.  Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Farah Logna; Bin Bao; Philip A Philip; Murray Korc; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

7.  Usefulness of KL-6 in the subtyping of intraductal papillary mucinous neoplasia of the pancreas, including carcinoma, dysplasia, and hyperplasia.

Authors:  Yuji Ohtsuki; Ryohei Watanabe; Masashi Kimura; Katsuyoshi Nomura; Tomoharu Maeda; Katsumi Kito; Miyuki Takeji; Gang-Hong Lee; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2014-06-08       Impact factor: 2.309

8.  Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Olca Basturk; Sun M Chung; Ralph H Hruban; N Volkan Adsay; Gokce Askan; Christine Iacobuzio-Donahue; Serdar Balci; Sui Y Zee; Bahar Memis; Jinru Shia; David S Klimstra
Journal:  Virchows Arch       Date:  2016-09-03       Impact factor: 4.064

9.  Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes.

Authors:  Vicente Morales-Oyarvide; Mari Mino-Kenudson; Cristina R Ferrone; Andrew L Warshaw; Keith D Lillemoe; Dushyant V Sahani; Ilaria Pergolini; Marc A Attiyeh; Mohammad Al Efishat; Neda Rezaee; Ralph H Hruban; Jin He; Matthew J Weiss; Peter J Allen; Christopher L Wolfgang; Carlos Fernández-Del Castillo
Journal:  J Gastrointest Surg       Date:  2017-10-18       Impact factor: 3.452

10.  Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct.

Authors:  Klaus Sahora; Carlos Fernández-del Castillo; Fei Dong; Giovanni Marchegiani; Sarah P Thayer; Cristina R Ferrone; Dushyant V Sahani; William R Brugge; Andrew L Warshaw; Keith D Lillemoe; Mari Mino-Kenudson
Journal:  Surgery       Date:  2014-07-28       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.